Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Mayo Clinic
Checkpoint Therapeutics, Inc.
Fate Therapeutics
Pfizer
Ludwig Institute for Cancer Research
University of Zurich
Incyte Corporation
MultiVir, Inc.